---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-018311"
form_type: "8-K"
ticker: "RLAY"
cik: "0001812364"
company_name: "Relay Therapeutics, Inc."
filed_at: "2022-09-12T23:59:59+00:00"
generated_at: "2026-06-23T11:16:16.172445+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relay Therapeutics reports 88% interim ORR for RLY-4008 in FGFR2-fusion CCA at pivotal dose

## Summary
- 15 of 17 efficacy-evaluable patients at 70 mg QD achieved partial response (88% interim ORR); 14 confirmed, 1 unconfirmed.
- 13 of 15 responders remain on treatment; one patient resected with curative intent; two stable disease patients continue.
- Across all doses/schedules, 24 of 38 FGFRi-naïve FGFR2-fusion CCA patients had partial response (63% interim ORR).
- No Grade 4 or 5 adverse events; off-target toxicities (hyperphosphatemia, diarrhea) clinically insignificant.
- Pivotal cohort enrollment expected to complete in H2 2023; initial non-CCA data and full dose escalation data expected in 2023.

## SEC filing metadata
- accession: 0000950170-22-018311
- form_type: 8-K
- ticker: RLAY
- cik: 0001812364
- company_name: Relay Therapeutics, Inc.
- filed_at: 2022-09-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812364/000095017022018311/0000950170-22-018311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812364/000095017022018311/rlay-20220911.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-018311
- JSON: https://secwatch.observer/filing/0000950170-22-018311.json
- Plain text: https://secwatch.observer/filing/0000950170-22-018311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.